SCHEMBL6508962

SCHEMBL6508962

Cc1[nH]nc2c1c(=O)[nH]c1ccc(O)cc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 13/20 0.74
PARP1 P09874 1/20 0.43
ROCK2 O75116 1/20 0.41
GAA P10253 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
CASP6 P55212 1/20 0.41
KMT2A Q03164 1/20 0.41
WEE1 P30291 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HTR1D P28221 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTR7 P34969 1/20 0.40
HTR3A P46098 1/20 0.40
HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6046750 0.83 CHEK1 (0.74) CHEK1
SCHEMBL6507585 0.83 CHEK1 (1.00) CHEK1GAACYP1A2
SCHEMBL6514882 0.83 CHEK1 (0.74) CHEK1PARP1
Hydrochloric Acid SCHEMBL6508722 0.82 CHEK1 (0.72) CHEK1PARP1
SCHEMBL6509801 0.79 CHEK1 (0.67) CHEK1PARP1MEN1POLBKMT2A
SCHEMBL4006355 0.77 CHEK1 (1.00) CHEK1GAAMEN1POLBKMT2A
SCHEMBL4017149 0.73 CHEK1 (1.00) CHEK1
SCHEMBL6046741 0.70 CHEK1 (0.55) CHEK1
SCHEMBL2442863 0.69 PARP1 (0.69) CHEK1PARP1ROCK2GAATDP1
SCHEMBL2552481 0.69 CHEK1 (0.45) CHEK1PARP1ROCK2GAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005030735-A1 TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 WO claimed
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005030735-A1 TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 WO disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885PARP1 1091/4885ROCK2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.